Comparison of the Treatment Efficacy of 161Tb- and 177Lu-Labeled GRPR Antagonists in PC3 Tumor-Bearing Mice

Thomas Günther; Abraham Moses; Elisabeth Gunter; Madeleine Landry; Stijn Ramaekers; Michiel Van de Voorde; Maarten Ooms; Bernard Ponsard; Corinne Beinat

Comparison of the Treatment Efficacy of 161Tb- and 177Lu-Labeled GRPR Antagonists in PC3 Tumor-Bearing Mice

Thomas Günther, Abraham Moses, Elisabeth Gunter, Madeleine Landry, Stijn Ramaekers, Michiel Van de Voorde, Maarten Ooms, Bernard Ponsard, Corinne Beinat

Research output › peer-review

Abstract

Introduction: Based on reports on the increased therapeutic efficacy of 161Tb- over 177Lu-labeled antagonists (1), and the promising in vitro and in vivo data of 177Lu- and 161Tb-labeled gastrin-releasing peptide receptor (GRPR) ligands, RM2 (DOTA-Pip5-D-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2) and AMTG (α-Me-Trp8-RM2) (2), we completed a treatment study in PC3 tumor-bearing animals to investigate whether these 161Tb-labeled derivatives might be a superior treatment option for GRPR-expressing malignancies than their 177Lu-labeled analogs.

Original language	English
Article number	251613
Number of pages	1
Journal	Journal of Nuclear Medicine
Volume	66
Issue number	Supplement 1
State	Published - 2025

Access to Document

https://jnm.snmjournals.org/content/66/supplement_1/251613License: Unspecified

Cite this

@article{1039dd22ebc74d3287d4a5db13beba7e,

title = "Comparison of the Treatment Efficacy of 161Tb- and 177Lu-Labeled GRPR Antagonists in PC3 Tumor-Bearing Mice",

abstract = "Introduction: Based on reports on the increased therapeutic efficacy of 161Tb- over 177Lu-labeled antagonists (1), and the promising in vitro and in vivo data of 177Lu- and 161Tb-labeled gastrin-releasing peptide receptor (GRPR) ligands, RM2 (DOTA-Pip5-D-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2) and AMTG (α-Me-Trp8-RM2) (2), we completed a treatment study in PC3 tumor-bearing animals to investigate whether these 161Tb-labeled derivatives might be a superior treatment option for GRPR-expressing malignancies than their 177Lu-labeled analogs.",

keywords = "161Tb, 177Lu",

author = "Thomas G{\"u}nther and Abraham Moses and Elisabeth Gunter and Madeleine Landry and Stijn Ramaekers and \{Van de Voorde\}, Michiel and Maarten Ooms and Bernard Ponsard and Corinne Beinat",

note = "Score=1",

year = "2025",

language = "English",

volume = "66",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "Supplement 1",

}

TY - JOUR

T1 - Comparison of the Treatment Efficacy of 161Tb- and 177Lu-Labeled GRPR Antagonists in PC3 Tumor-Bearing Mice

AU - Günther, Thomas

AU - Moses, Abraham

AU - Gunter, Elisabeth

AU - Landry, Madeleine

AU - Ramaekers, Stijn

AU - Van de Voorde, Michiel

AU - Ooms, Maarten

AU - Ponsard, Bernard

AU - Beinat, Corinne

N1 - Score=1

PY - 2025

Y1 - 2025

N2 - Introduction: Based on reports on the increased therapeutic efficacy of 161Tb- over 177Lu-labeled antagonists (1), and the promising in vitro and in vivo data of 177Lu- and 161Tb-labeled gastrin-releasing peptide receptor (GRPR) ligands, RM2 (DOTA-Pip5-D-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2) and AMTG (α-Me-Trp8-RM2) (2), we completed a treatment study in PC3 tumor-bearing animals to investigate whether these 161Tb-labeled derivatives might be a superior treatment option for GRPR-expressing malignancies than their 177Lu-labeled analogs.

AB - Introduction: Based on reports on the increased therapeutic efficacy of 161Tb- over 177Lu-labeled antagonists (1), and the promising in vitro and in vivo data of 177Lu- and 161Tb-labeled gastrin-releasing peptide receptor (GRPR) ligands, RM2 (DOTA-Pip5-D-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2) and AMTG (α-Me-Trp8-RM2) (2), we completed a treatment study in PC3 tumor-bearing animals to investigate whether these 161Tb-labeled derivatives might be a superior treatment option for GRPR-expressing malignancies than their 177Lu-labeled analogs.

KW - 161Tb

KW - 177Lu

M3 - Meeting abstract

SN - 0161-5505

VL - 66

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - Supplement 1

M1 - 251613

ER -